You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星医药(02196.HK)与BioNTech拟於上海组合营生产新冠疫苗 股份早段升两成
阿思达克 05-10 09:48
复星医药(02196.HK)公布,与BioNTech订立一份条款书,为新冠疫苗产品的本地化生产及商业化而拟设立一家合资公司,双方将分别持股50%,为期15年,注册地为上海。

根据该条款书,复星医药产业同意以现金及/或有形、无形资产(包括厂房及生产设施等)向合资公司作价出资总额不超过1亿美元,而BioNTech以其相关生产技术和专有技术许可等无形资产作价出资总额不超过1亿美元。

复星医药产业应提供具备年产能可达10亿剂新冠疫苗产品的生产设施,并作为出资的一部分注入合资公司。BioNTech应当负责办理有关技术转移(通过订立技术许可协议)事宜及提供相关技术支持,且应确保有充足的适当人员。BioNTech就相关技术转移及支持所产生的合理开支应由合资公司承担。

另外,合资公司应聘请复星医药产业之联属公司作为合同销售组织以提供合资公司的新冠疫苗产品在中国境内的推广及销售服务。合资公司应按照条款书约定向合同销售组织支付服务费。

受消息刺激,复星医药股份最新报60.5元,升20.9%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account